Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study

By Tsavaris Nicolas   Kosmas Christos   Skopelitis Helias   Gouveris Panagiotis   Kopteridis Petros   Loukeris Dioynissis   Sigala Frantzeska   Zorbala-Sypsa Alexandra   Felekouras Evangelos   Papalambros Efstathios  

Investigational New Drugs, Vol. 23, Iss. 4, 2005-08 ,pp. : 369-375

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies

By Argiris Athanassios  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1575-1584

Springer Publishing Company

Access to resources Recommend Favorite

A Phase I Trial of Daily Oral 4′-N-Benzoyl-Staurosporine in Combination with Protracted Continuous Infusion 5-Fluorouracil in Patients with Advanced Solid Malignancies

By Eder Jr Joseph P.   Garcia-Carbonero Rocio   Clark Jeffrey W.   Supko Jeffrey G.   Puchalski Thomas A.   Ryan David P.   Deluca Pamela   Wozniak Antoinette   Campbell Angela   Rothermel John   LoRusso Patricia  

Investigational New Drugs, Vol. 22, Iss. 2, 2004-04 ,pp. : 139-150

Springer Publishing Company

Access to resources Recommend Favorite

A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers

By Ciuleanu T.   Diculescu M.   Hoepffner N.   Trojan J.   Sailer V.   Zalupski M.   Herrmann T.   Roth A.   Chick J.   Brock K.   Albert D.   Philip P.  

Investigational New Drugs, Vol. 25, Iss. 4, 2007-08 ,pp. : 385-390

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

By Deenen Maarten  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1557-1565

Springer Publishing Company

Access to resources Recommend Favorite